ACIP Dengue Vaccine Workgroup

Katherine A. Poehling, MD, MPH
Wilbur Chen, MD, MSc
ACIP Members and Workgroup Co-Chairs
Advisory Committee on Immunization Practices
ACIP Meeting February 24, 2021

ACIP Dengue Vaccines Workgroup

ACIP Members Liaison Representatives Anita Shet

Kathy Poehling (Co-chair) Elizabeth Barnett (AAP) Steve Waterman

Wilbur Chen (Co-Chair) Rob Schechter (AIM)

Beth Bell CDC Contributors

Veronica McNally Consultants Laura Adams

Edwin Asturias Mimi Eckert

CDC Lead Robert Atmar Rachel Eidex

Alan Barrett Susan Hills

Anna Durbin Terri Hyde

Ines Esquilin Mike McNeil

Tony Marfin Jorge Munoz

Hal Margolis Erin Staples

Kristen Pierce Cindy Weinbaum

Ex Officio Members

Gabriela Paz-Bailey

Kaitlyn Morabito (NIH)

Ralph LeBlanc (FDA)

Kirk Prutzman (FDA)

Srihari Seshadri (DOD)

Dengue vaccine workgroup timeline

2019

Phase 3 results
Safety & pharmacovigilance
GRADE
Cost effectiveness
Dengue Diagnostics
Partially effective vaccines
Dengue vaccine in Philippines
VRBPAC review
FDA approval

2021

Dengue IgG test evaluation
Evidence to
recommendations
framework (EtR)
Draft recommendations to
ACIP

2017

Dengue epi and vaccine development









2018

WG on hold

Flavivirus WG split

Dengue Vaccine Workgroup is formed

2020

Vaccine acceptability
WHO global position
Feasibility
Health Equity

Dengue Vaccine Workgroup Discussions Nov 2020-Feb 2021

- Zika virus infection enhances future risk of severe dengue disease –
 Lea Katzelnick, UC Berkley
- Update on development status of a new dengue IgG rapid test to determine past infection – Stephen Savarino, Sanofi
- Feasibility of CYD-TDV vaccination program Steve Waterman, CDC
- CYD-TDV and Health Equity -Laura Adams, CDC
- Evaluation of commercial dengue IgG tests Freddy Medina, CDC
- Straw poll and discussion on evidence to recommendations sections –
 Gabriela Paz-Bailey

Importance of a specific test for pre-vaccination screening

- CYD-TCV vaccine presents novel challenges due to requirement of pre-vaccination screening
- A test for pre-vaccination dengue screening needs to be specific to minimize vaccination of seronegative children and sensitive to maximize identification of children who can benefit from the vaccine
- The workgroup is reviewing data and considering including recommended test performance characteristics in the MMWR accompanying future ACIP recommendations

Anticipated ACIP Schedule 2021

 Further workgroup discussions to finalize the evidence to recommendations framework (EtR)

- ACIP Spring 2021 Meeting
 - EtR and draft WG recommendations
- ACIP June 2021 Meeting
 - ACIP vote CYD TDV recommendations

Presentation

Evaluation of Commercial Dengue Virus IgG Tests for Pre-vaccination Screening

Freddy Medina, PhD

Immunodiagnostic Activity Lead

Dengue Branch Surveillance and Research Laboratory

Centers for Disease Control and Prevention

Feedback

• Are there other considerations the workgroup should address?